International Niemann–Pick Disease Alliance

Updates

  1. Summary of INPDA’s face to face meeting, Mainz, October 2015

    The attached file contains a summary of the presentations and topics covered during the fourth biennial face to face meeting of INPDA members. This took place in Mainz, Germany, at the end of October 2015. Looking forward to 2017...

    Read story
  2. Positive Review of Paediatric Investigation Plan (PIP) for AIDNPC

    NEWS RELEASE – Copenhagen, 10 February 2016 Positive Review of Paediatric Investigation Plan (PIP) for AIDNPC . EMA’s Paediatric Committee (PDCO) recommends that the Committee for Medicinal Products for Human Use (CHMP) approve Orphazyme’s PIP for use of arimoclomol in treating patients suffering from Niemann-Pick disease type C (NP-C). The...

    Read story
  3. INPDA receives Patient Advocacy Leadership Award

    Now in its fifth year, Genzyme’s Patient Advocacy Leadership Awards (PAL Awards) program supports non-profit organizations that serve the lysosomal storage disorder (LSD) patient community. From Genzyme “As an independent voice, patient organizations play a vital role in providing...

    Read story
  4. AIDNPC – teleconference minutes 26th November

    A teleconference was hosted by Orphazyme 26th November 2015, to provide an update to patient organisations regarding the development of Arimoclomol in the AIDNPC programme. These calls will continue monthly – the next scheduled to take place 14th January...

    Read story
  5. AIDNPC Clinical Programme change: Earlier initiation of Interventional study

    The INPDA and its member groups have received the following update from Orphazyme, ApS: AIDNPC Clinical Programme change: Earlier initiation of Interventional study (CT-ORZY-NPC-002; Arimoclomol treatment). After valuable dialogue with regulators and patient organizations on the design of the Observational and Interventional...

    Read story
  6. “IMAGINE”, our NP-C awareness short film, now subtitled in ten languages!

    “IMAGINE” follows the story Millie, who dreams of being a dancer yet suffers from Niemann-Pick Type C. Already viewed over 160,000 times on YouTube, we’re delighted that the English script has now been subtitled in 10 languages – Arabic,...

    Read story
  7. Launch of dedicated website to Orphazyme’s AIDNPC clinical programme

    Copenhagen, 16 September 2015. A dedicated website to AIDNPC has been launched. The site describes Orphazyme’s clinical programme to investigate the orally available small molecule arimoclomol in Niemann-Pick disease type C. The website offers to NP-C patients a tool...

    Read story
  8. Orphazyme announces update to its AIDNPC clinical programme

    Orphazyme has announced a further update to its NP-C clinical programme. Arimoclomol will require the performance of a double-blinded clinical trial with a control group. The control group means that a third of patients enrolled will receive a placebo for...

    Read story
  9. Great Divide Mountain Bike Ride for “Think Again. Think NPC”

    Felix Schleuniger of Switzerland arrived in Banff, Alberta Canada on July 18th, 2015 at 1:00pm on schedule at the Banff Springs Hotel after biking 2,500 miles from Albuquerque, New Mexico USA on the Great Divide Mountain Bike Route for...

    Read story
  10. “IMAGINE” awareness film now available with subtitles

    The “IMAGINE” short film, which follows the story of Millie, a little girl who dreams of being a dancer, yet suffers from Niemann Pick Type C, is now available with subtitles in Spanish, German, Polish and French – more to...

    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...